Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azithromycin (PLIVA)
- Development stage
- Preclinical
- Lead developer
- ILiAD Biotechnologies
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Azithromycin** is a semisynthetic macrolide antibiotic used as the antibiotic post-exposure prophylaxis intervention in Vanderbilt University's pertussis-exposure study of Tdap-vaccinated healthcare workers. It binds bacterial 23S ribosomal RNA within the 50S ribosomal subunit, inhibiting peptide translocation and bacterial protein synthesis. In this study context, azithromycin was evaluated as post-exposure prophylaxis following exposure to *Bordetella pertussis*, rather than as a distinct proprietary drug candidate.
- Other names
- Antibiotic PEP-Vanderbilt University-pertussis
02
Targets
Bacterial 50S ribosomal subunit
Beyond the preview
Go deeper on azithromycin (PLIVA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azithromycin (PLIVA).